Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
Kim, Sunghee , Go, Alan S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Singer, Daniel E. , Thomas, Laine , Blanco, Rosalia , Piccini, Jonathan P. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and, Jackson, Larry R. , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and

Mayo Clinic

Journal of the American Heart Association | September 14, 2018 | Volume: 7 | Issue: 16 | Pages: No page available

10.1161/jaha.118.008764 | PMID 30369317 Get It

Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA 2 DS 2 VASc=1) (or women with CHA 2 DS 2 VASc=2) a variety of treatment strategies may be considered. However, in clinical practice, patterns of treatment in these “low‐risk” patients are not well described. The objective of this analysis is to define thromboembolic event rates and to describe treatment patterns in patients with low‐risk CHA 2 DS 2 VASc scores. Methods and Results We compared characteristics, treatment strategies, and outcomes among patients with a CHA 2 DS 2 VASc=0, CHA 2 DS 2 VASc=1, females with a CHA 2 DS 2 VASc=2, and CHA 2 DS 2 VASc ≥2 in ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) I & II. Compared with CHA 2 DS 2 VASc ≥2 patients (84.2%), those with a CHA 2 DS 2 VASc=0 (60.3%), 1 (69.9%), and females with a CHA 2 DS 2 VASc score=2 (72.4%) were significantly less often treated with oral anticoagulation ( P <0.0001). Stroke rates were low overall and ranged from 0 per 100 patient‐years in those with CHA 2 DS 2 VASc=0, 0.8 (95% confidence interval [CI] [0.5–1.2]) in those with CHA 2 DS 2 VASc=1, 0.8 (95% CI [0.4–1.6]) in females with a CHA 2 DS 2 VASc score=2, and 1.7 (95% CI [1.6–1.9]) in CHA 2 DS 2 VASc ≥2. All‐cause mortality (per 100 patient‐years) was highest in females with a CHA 2 DS 2 VASc score=2 (1.4) (95% CI [0.8–2.3]), compared with patients with a CHA 2 DS 2 VASc=0 (0.2) (95% CI [0.1–1.0]), and CHA 2 DS 2 VASc=1 (1.0) (95% CI [0.7–1.4]), but lower than patients with a CHA 2 DS 2 VASc ≥2 (5.7) (95% CI [5.4–6.0]). Conclusion The majority of CHA 2 DS 2 VASc=0‐1 patients are treated with oral anticoagulation. In addition, the absolute risks of death and stroke/transient ischemic attack were low among both male and females CHA 2 DS 2 VASc=0‐1 as well as among females with a CHA 2 DS 2 VASc score=2. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.
Risk of Appropriate Therapy and Death Before Therapy After Implantable Cardioverter-Defibrillator Generator Replacement
Witt, Chance M. , Waks, Jonathan W. , Mehta, Ramila A. , Friedman, Paul A. , Kramer, Daniel B. , Buxton, Alfred E. , Mulpuru, Siva K. , Hodge, David O. , Lushinsky, Emilie C., Mulholland, Megan B., Cha, Yong‐Mei , Madhavan, Malini , Noseworthy, Peter A. , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 14, 2018 | Volume: 11 | Issue: 8 | Pages: No page available

10.1161/circep.117.006155 | PMID 30354311 Get It

Background The decision to initially implant an implantable cardioverter-defibrillator (ICD) is informed by robust randomized controlled trials, but no such data exist to guide the decision to replace an ICD generator. In this study, we aimed to determine outcomes after ICD generator replacement. Methods All patients with ischemic or nonischemic cardiomyopathy who underwent ICD generator replacement from 2001 to 2011 at Mayo Clinic, MN, or Beth Israel Deaconess Medical Center, MA, were included. Outcomes included (1) appropriate therapy after generator replacement and (2) death before appropriate therapy after generator replacement. Cox proportional hazards modeling was used to determine the associations between patient characteristics and outcomes. Results In 1421 patients undergoing ICD generator replacement (mean±SD age 69.6±12.1 years, 81% male), appropriate therapy occurred after replacement in 435 patients (30.6%) over a mean follow-up of 2.7±2.6 years. Associated factors included lower left ventricular ejection fraction and history of appropriate therapy before generator replacement. Death before appropriate ICD therapy occurred in 336 (23.7%) patients. Older age, lower left ventricular ejection fraction, and noncardiac comorbidities, including diabetes mellitus, chronic lung disease, peripheral vascular disease, lower hemoglobin, and lower glomerular filtration rate, were associated with greater risk of death before appropriate therapy. A progressive increase in mortality was observed with aggregation of these noncardiac comorbidities. Conclusions The decision to replace the ICD should take into consideration not only left ventricular ejection fraction and history of ventricular arrhythmias, but also comorbid illnesses that may impact the duration and the quality of life.
Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus
Steinhart, A. Hillary , Bressler, Brian , Khanna, Reena , Afif, Waqqas , Bernstein, Çharles N. , Bitton, Alain , Borgaonkar, Mark , Chauhan, Usha, Halloran, Brendan P. , Jones, Jennifer , Kennedy, Erin , Meddings, Jonathan B., Plamondon, Sophie , Rosenfeld, Greg , Seow, Cynthia H. , Williams, Chadwick, Panaccione, Remo , Targownik, Laura E. , Marshall, John K. , Bernstein, Charles Noah , Leontiadis, Grigorios I. , Loftus, Edward V. , Moayyedi, Paul , Murthy, Sanjay K. , Schwartz, David A.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | September 13, 2018 | Volume: 1 | Issue: 4 | Pages: 141-154

10.1093/jcag/gwy047 | PMID 31799497 Get It

Sex Differences in Resting Metabolic Rate Among Athletes
Jagim, Andrew R. , Camic, Clayton L., Askow, Andy, Luedke, Joel, Erickson, Jacob L. , Jones, Margaret T. , Oliver, Jonathan M. , Askow, Andrew T. , Erickson, Jacob, Jagim, Andrew R , Askow, Andrew T , Kerksick, Chad M.

Mayo Clinic

Journal of Strength and Conditioning Research | September 8, 2018 | Volume: 33 | Issue: 11 | Pages: 3008-3014

10.1519/jsc.0000000000002813 | PMID 30199450 Get It

Abstract Jagim, AR, Camic, CL, Askow, A, Luedke, J, Erickson, J, Kerksick, CM, Jones, MT, and Oliver, JM. Sex differences in resting metabolic rate among athletes. J Strength Cond Res 33(11): 3008–3014, 2019—The purpose of this study was to compare differences in resting metabolic rate (RMR) between sexes in Division III National Collegiate Athletic Association (NCAA) collegiate athletes and to identify predictors of RMR. Sixty-eight male (M) (age: 20.1 ± 1.5 years; height: 181.8 ± 5.9 cm; body mass (BM): 93.7 ± 16.3 kg; and body fat%: 16.3 ± 8.6%) and 48 female (F) athletes (age: 19.4 ± 1.3 years; height: 166.5 ± 6.0 cm; BM: 63.4 ± 12.7 kg; and body fat%: 21.5 ± 6.3%) participated in a single day of testing, which included determination of RMR using indirect calorimetry and air displacement plethysmography to measure fat mass and fat-free mass (FFM). An independent-samples t -test was used to compare differences in body composition and RMR between sexes, and regression analysis was used to identify predictors of RMR. Men had a significantly higher absolute RMR (M: 2,481 ± 209 vs. F: 1,553 ± 193 kcals·d −1 ; p < 0.001), but when adjusted for BM (M: 25.6 ± 8.3 vs. F: 25.9 ± 2.5 kcals·kg −1 BM per day; p = 0.82) and FFM (M: 31.1 ± 10.6 vs. F: 33.6 ± 3.8 kcals·kg −1 FFM per day; p = 0.12), these differences became nonsignificant. Regression analysis indicated that BM in both men (β = 0.73) and women (β = 0.88) was the strongest predictor of RMR. The results of the current study indicate minimal differences in RMR between sexes among athletic populations when adjusted for BM and FFM. In the current group of athletes, BM seems to account for the largest variability in RMR.
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
Martin, Thomas G. , Vij, Ravi , Cole, Craig E. , Atanackovic, Djordje , Zonder, Jeffrey A. , Bensinger, William, Zimmerman, Todd M., Lendvai, Nikoletta , Gasparetto, Cristina , Kumar, Shaji , Oprea, Corina, Richter, Joshua , Kaufman, Jonathan L. , Mıkhael, Joseph , Dimopoulos, Meletios Α. , Hari, Parameswaran , Ocio, Enrique M. , Charpentier, Éric , Strickland, Stephen Anthony , Miguel, Jesús F. San

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8005-8005

10.1200/jco.2016.34.15_suppl.8005 Get It

NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE.
Wolin, Edward M. , Chasen, Beth, Kulke, Matthew H. , Caplin, Martyn , Baum, Richard P. , Hobday, Timothy J. , Hendifar, Andrew , Öberg, Kjell E., Sierra, Maribel Lopera , Kwekkeboom, Dik J., Ruszniewski, Philippe, Krenning, Eric P. , Kunz, Pamela L. , Strosberg, Jonathan , Bushnell, David

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2016.34.15_suppl.4005 Get It

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).
Demeure, Michael J. , Armaghany, Tannaz , Ejadi, Samuel, Ramanathan, Ramesh K., Elfiky, Aymen, Smith, David C. , Sekar, Shobana , Carpten, John D. , Fredlund, Paul, Niforos, Demi, Dye, Andrew, Gahir, Sarabjit, Semple, Sean C., Kowalski, Mark , Strosberg, Jonathan , Whitsett, Timothy G. , Liang, Winnie S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2547-2547

10.1200/jco.2016.34.15_suppl.2547 Get It

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).
Long, Georgina V. , Eroglu, Zeynep , Infante, Jeffrey R., Patel, Sapna P. , Johnson, Douglas B. , González, René , Hamid, Omid , Schuchter, Lynn M. , Sharfman, William H. , Mookerjee, Bijoyesh, Gasal, Eduard, Redhu, Suman, Infante, Jon , Infante, Jon , Long, Georgina V , Daud, Adil , Kefford, Richard , Cebon, Jonathan Simon , McWilliams, Robert R. , Weber, Jeffrey S. , Flaherty, Keith T.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 9505-9505

10.1200/jco.2017.35.15_suppl.9505 Get It

9505 Background: D (BRAF inhibitor) + T (MEK inhibitor) combination therapy is associated with rapid clinical responses and has improved clinical outcomes in pts with BRAFV600–mutant MM, but long-term (˃ 3 y) clinical efficacy and safety data are limited. The longest follow-up to date of a randomized trial evaluating D+T at the approved dose (150 mg BID/2 mg QD [150/2]) was of the phase II study BRF113220 (part C; median, 45.6 mo) in which durable outcomes were achieved in some pts with BRAFV600–mutant MM (3-y OS, 38%). Here, we report updated 5-y landmark analyses to further characterize the impact of D+T in MM. Methods: Pts with BRAFV600–mutant mm enrolled in BRF113220 part C (NCT01072175) were randomized 1:1:1 to receive monotherapy D (150 mg BID), D+T (150 mg BID/1 mg QD), or D+T (150/2). Pts who progressed on D alone could cross over to the D+T 150/2 arm. Pt disposition, pt demographics, and 4- and 5-y efficacy and safety were analyzed for both the D-alone and D+T (approved 150/2 dose) arms. Results: This updated analysis represents an additional ≈ 2 y of follow-up (D and D+T arms; n = 54 each). As of 13 Oct 2016, 45 pts (83%) on D alone had crossed over to D+T. 20 pts were ongoing (D, n = 7 [13%]; D+T, n = 13 [24%]); 80% of D pts and 70% of D+T pts had died. D+T OS remained superior to D alone. The 4- and 5-y OS rates with D+T were 30% and 28%, respectively, demonstrating a stabilization of the OS curve. The PFS curve for D+T also remained stable (4- and 5-y: both 13%). Consistent with earlier results, the best OS for pts who received D+T was seen in pts with normal LDH (5-y, 45%) and normal LDH with disease in < 3 organ sites (5-y, 51%). At the 5-y landmark, 1 additional pt who received D+T improved from a partial to a complete response. Additional follow-up revealed no new safety signals with D+T. Detailed analyses of D crossover pts, responders, and post-progression therapy will be presented. Conclusions: This longest follow-up to date of BRAF + MEK inhibitor combination therapy in pts with BRAFV600–mutant mm revealed stable OS and PFS lasting ≥ 5 y with consistent tolerability. These results demonstrate that some pts with mm can achieve durable benefit with D+T therapy. Clinical trial information: NCT01072175.
Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma.
Nowakowski, Grzegorz S. , Kalakonda, Nagesh , Truemper, Lorenz , Everaus, Hele, Jaeger, Jonathan, Manzke, Oliver, Investigators, And the MEDI4736-DLBCL-001 Trial, Fustier, Pierre , Jäger, Ulrich , Investigators, And the MEDI4736-DLBCL-001 Trial

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS7573-TPS7573

10.1200/jco.2017.35.15_suppl.tps7573 Get It

TPS7573 Background: The PD-1/PD-L1 pathway is an important immune checkpoint used by tumor cells and may provide an effective target for enhancing anticancer immune response. In DLBCL, high PD-L1 expression has been identified as a negative prognostic factor for overall survival. Durvalumab (MEDI4736) is a high-affinity human IgG1 monoclonal Ab that selectively blocks PD-L1 binding to PD-1 and CD80, and preliminary preclinical and clinical activity support the study of durvalumab in high-risk DLBCL subtypes. The primary study objective is to explore the clinical activity of durvalumab with R-CHOP in non-activated B-cell–like (non-ABC) and durvalumab with lenalidomide + R-CHOP (R2-CHOP) in ABC previously untreated DLBCL; secondary objectives are to evaluate safety and identify biomarkers predictive of clinical response. Methods: This is a phase II, two-arm, open-label, global, multicenter study of durvalumab combinations in patients with previously untreated, high-risk DLBCL (MEDI4736-DLBCL-001; EUDRA CT 2015-005173-20; NCT03003520). High risk was defined as Ann Arbor stage III/IV or II with bulky disease (≥7.0 cm), along with intermediate-high/high IPI ≥3 or NCCN-IPI ≥4; patients must also have CD20+ DLBCL, ECOG PS 0-2, and no prior antilymphoma therapy. All patients receive durvalumab + R-CHOP21 in induction cycle 1 simultaneous to cell-of-origin (COO) analysis by gene expression profiling with NanoString technology. Beginning with cycle 2, Arm A (non-ABC) receives durvalumab 1125 mg IV on day 1 with 6 or 8 cycles of R-CHOP21; Arm B (ABC) receives the same durvalumab + R-CHOP21 doses with oral lenalidomide 15 mg/day on days 1-14. Both arms receive durvalumab consolidation 1500 mg IV on day 1 q28d for ≤12 months from induction cycle 1, day 1. The primary endpoint is 2-y progression-free survival (PFS); secondary endpoints include clinical response to treatment in biomarker-defined subpopulations (tumor and peripheral blood) and safety as assessed per NCI CTCAE v4.03 criteria. Exploratory endpoints include PFS at 12 mo, complete response, and PK/PD. Recruitment is ongoing, with a target enrollment of 120 patients. Clinical trial information: NCT03003520.